53例子宫腺肌病患者临床理化指标分析
Analysis of Clinical and Physicochemical Indicators in 53 Cases of Adenomyosis Patients
DOI: 10.12677/jcpm.2024.34246, PDF, HTML, XML,    科研立项经费支持
作者: 麦晓珊*:广州中医药大学第二临床医学院,广东 广州;冉青珍#:广东省中医院妇科,广东 广州
关键词: 子宫腺肌病慢性炎症免疫功能凝血功能实验室检查Adenomyosis Chronic Inflammation Immune Function Blood Coagulation Function Laboratory Examination
摘要: 目的:分析子宫腺肌病(adenomyosis)的临床理化指标特征,并探讨腺肌病与炎症状态、营养状态及高凝状态的相关性。方法:回顾性收集2021年1月~2022年12月于广东省中医院53例经手术和病理诊断确认的子宫腺肌病患者病历资料作为研究对象,50例其他良性妇科疾病患者病历资料作为对照组。采用SPSS 24.0软件进行数据处理比较两组的全血细胞计数、凝血功能指标、肝肾功能指标以及炎症相关指标,包括单核细胞与淋巴细胞比值(monocyte/lymphocyte ratio, MLR)、血小板与淋巴细胞比值(platelet/lymphocyte ratio, PLR)等。结果:子宫腺肌病患者的单核细胞计数(P = 0.012)、血小板计数(P < 0.000)、MLR (P = 0.013)和PLR (P = 0.01)均显著高于对照组,而血红蛋白(P < 0.000)、总胆红素(P = 0.001)和白蛋白(P=0.002)水平则显著低于对照组。结论:本研究发现子宫腺肌病患者在临床理化检验方面存在一定的特征。呈现出一定的炎症反应状态、低营养状态、高凝状态。
Abstract: Objective: This paper aims to analyze the clinical and physicochemical characteristics of adenomyosis and investigate the correlation between adenomyosis and inflammatory status, nutritional status, and hypercoagulable state. Methods: The medical records of 53 patients diagnosed with adenomyosis through surgical and pathological diagnosis were included as the subjects of this study, at Guangdong Provincial Hospital of Traditional Chinese Medicine from January 2021 to December 2022, whereas the records of 50 patients in other benign gynecological conditions served as the control group. Data processing was conducted by SPSS 24.0 software to compare the complete blood count (CBC), coagulation function test indexes, liver and renal function tests, and inflammation markers (including the monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), etc.) between the two groups; Results: Patients with adenomyosis exhibited significantly elevated monocyte counts (P = 0.012), platelet counts (P < 0.000), MLR (P=0.013) and PLR (P = 0.01) compared to the control group. Conversely, levels of hemoglobin (P < 0.000), total bilirubin (P = 0.001), and albumin (P = 0.002) were notably lower than those observed in the control group. Conclusion: This study has identified certain clinical and biochemical characteristics in patients with adenomyosis. These characteristics include states of inflammation, malnutrition, and hypercoagulability.
文章引用:麦晓珊, 冉青珍. 53例子宫腺肌病患者临床理化指标分析[J]. 临床个性化医学, 2024, 3(4): 1718-1724. https://doi.org/10.12677/jcpm.2024.34246

1. 引言

子宫腺肌病是一种常见的妇科疾病,其典型临床表现包括:子宫肥大、月经过多、痛经及不孕,这些症状严重损害了女性的生活质量。组织学上,子宫腺肌病以子宫肌层出现异位的子宫内膜组织(子宫内膜基质和腺体),并引发周围肌层平滑肌增生与肥大为特征[1]。目前子宫腺肌病的病理机制尚不明确,研究认为可能涉及多种因素,如子宫内膜–肌层界面的微创伤;子宫内膜对子宫肌层的侵袭增强;子宫肌层干细胞分化;逆流经血中子宫内膜细胞从浆膜侧浸润到子宫壁;异常局部类固醇和垂体激素诱导子宫腺肌病变;遗传学说;炎症刺激学说等[2]-[4]

近年来,关于子宫腺肌病的炎症刺激学说获得较多业内人士认可[5] [6],从分子生物学水平展示了炎症刺激与子宫腺肌病发病及疾病进展的关系。尚不足以应用于临床诊断和治疗。本项研究对53例子宫腺肌病患者的临床资料以及50例其他良性妇科疾病(包括:子宫内膜息肉、子宫内膜息肉样增生、子宫内膜单纯性增生)患者的常规理化检验资料进行了分析对比,旨在揭示子宫腺肌病患者的临床生化特征及其与炎症的相关性,为该病的早期临床诊断、预防、治疗提供有价值的指导。

2. 资料与方法

2.1. 研究对象

回顾分析53例2021年1月~2022年12月于广东省中医院因子宫腺肌症行全子宫切除术治疗患者的病历资料作为本次研究对象(以下简称腺肌组)。同时选取同期因“异常子宫出血”于我院进行宫腔镜手术,且不合并子宫腺肌症的其他良性妇科疾病患者50例作为对照组。本研究已获得广东省中医院伦理委员会的批准(批准号:YF2022-397-01)。并根据广东省中医院伦理委员会机构指南,同意豁免知情同意书。

2.2. 纳入标准

① 所有患者40 ≤ 年龄 ≤ 55;② 出院第一诊断为子宫腺肌症或子宫内膜息肉或子宫内膜息肉样增生或子宫内膜单纯性增生;③ 术前均经阴道超声或核磁共振检查;术后病理诊断证实为子宫腺肌症或子宫内膜息肉,子宫内膜息肉样增生,子宫内膜单纯性增生。

2.3. 排除标准

① 合并有严重肝肾功能不全、血液系统疾病、免疫系统疾病及恶性肿瘤;② “异常子宫出血”宫腔镜术前B超提示合并子宫腺肌症者;③ 子宫腺肌症子宫切除术后病理诊断提示子宫内膜息肉,子宫内膜息肉样增生,子宫内膜单纯性增生合并子宫腺肌症者;④ 宫腔镜术后病理或子宫切除术后病理提示子宫内膜炎、子宫内膜癌者。

2.4. 临床资料收集

收集患者一般信息,包括:年龄、孕次、体重指数[Body mass index,BMI = 体重(Kg)/身高2 (m2)]、基础疾病情况,如是否患有糖尿病、高血压、脂肪肝等,检验指标:① 血常规(白细胞计数、中性粒细胞计数、淋巴细胞计数、单核细胞计数、嗜酸性粒细胞计数、血红蛋白计数、血小板计数)、② 凝血功能(凝血酶原时间、凝血酶原国际标准值、纤维蛋白原、活化部分凝血酶时间、凝血酶时间)、③ 肝肾功能(谷丙转氨酶、谷草转氨酶、肌酐、肾小球滤过率)、④ 促甲状腺激素(thyroid stimulating hormone,TSH)、⑤ 炎症指标[中性粒细胞与淋巴细胞比值(NLR = 中性粒细胞计数/淋巴细胞计数)、单核细胞与淋巴细胞比值(MLR = 单核细胞计数/淋巴细胞计数)、血小板与淋巴细胞比值(PLR = 血小板计数/淋巴细胞计数)]。

2.5. 统计学方法

采用SPSS 24.0进行数据处理,正态分布定量资料的统计描述采用均数 ± 标准差( x ¯ ±s )表示,偏态分布定量资料的统计描述采用中位数以中位数(四分位数间距) [M(Q1, Q3)]表示。正态分布定量资料的差异性比较采用独立样本的t检验,偏态分布定量资料的差异性比较采用非参数秩和检验。计数资料用百分比表示[n(%)],采用χ2检验。P < 0.05为差异有统计学意义。

3. 结果

3.1. 两组患者一般临床资料比较

病历资料选择自2021~2022年,广东省中医院大德路院区妇科住院患者病历资料3007例。按纳入标准及排除标准审核资料后,纳入子宫腺肌病组病历资料53例(51.5%),对照组纳入病历资料50例(48.5%)。比较两组病例一般临床资料。子宫腺肌病组患者年龄为47 (45, 50)岁,对照组患者年龄为46.5 (42, 49)岁。两组年龄无统计学差异(P > 0.05),具有组间可比性。对两组患者孕产情况、BMI、合并高血压、合并糖尿病、合并脂肪肝比较,子宫腺肌病组合并脂肪肝比例高于对照组,差异有统计学意义(P < 0.05),如表1

3.2. 两组患者实验室检查指标及炎症指标比较

子宫腺肌病组患者较对照组患者,单核细胞、血小板、MLR、PLR升高,差异具有统计学意义(P < 0.05)。而血红蛋白、总胆红素、白蛋白、凝血酶时间较对照组低,差异具有统计学意义(P < 0.05),如表2

Table 1. Comparison of clinical data between the two groups

1. 两组临床资料对比

项目

子宫腺肌病组(n = 53)

对照组(n = 50)

t/χ2/Z

P

年龄

47 (45, 50)

46.5 (42, 49)

1.417

0.157

孕次

3 (2, 4)

3 (2, 4)

1.066

0.286

BMI

23.33 ± 2.67

22.29 ± 2.80

1.933

0.056

高血压

3 (5.66%)

1 (2%)

0.203

0.652

糖尿病

3 (5.66%)

0

1.257

0.262

脂肪肝*

12 (22.65%)

0

12.814

0.000

注:BMI (Body mass index) = 体重(Kg)/身高2 (m2);*P < 0.05。

Table 2. Comparison of biochemical indicators between the two groups

2. 两组生化指标对比

项目

子宫腺肌病组(n = 53)

对照组(n = 50)

t/χ2/Z

P

白细胞计数

6.07 ± 1.83

5.86 ± 1.40

0.679

0.499

中性粒细胞计数

3.97 (2.99, 5.01)

3.6 (3.19, 4.45)

0.749

0.454

淋巴细胞计数

1.52 (1.32, 1.82)

1.58 (1.17, 1.85)

0.168

0.886

嗜酸性粒细胞计数

0.09 (0.06, 0.13)

0.07 (0.04, 0.12)

1.689

0.091

单核细胞计数*

0.36 (0.29, 0.47)

0.31 (0.25, 0.38)

2.516

0.012

血红蛋白*

94.49 ± 27.51

120.32 ± 17.09

−5.658

0.000

血小板计数*

330 (278, 389.5)

278 (231.5, 317)

3.603

0.000

MLR*

0.23 (0.19, 0.32)

0.2 (0.16, 0.24)

2.488

0.013

PLR*

221.92 (176.08, 274.08)

175.71 (152, 232.71)

2.593

0.010

凝血酶原时间

12.78 ± 0.64

12.88 ± 0.58

0.896

0.372

凝血酶原活动度

108.87 ± 12.12

106.84 ± 11.22

0.88

0.381

凝血梅园国际标准化值

0.95 (0.91, 1.01)

0.97 (0.93, 1.00)

0.73

0.465

纤维蛋白原(FIB)

2.81 (2.39, 3.2)

2.92 (2.62, 3.21)

0.808

0.419

活化部分凝血活酶时间(APTT)

35.1 (33.1, 37.1)

36.45 (33.95, 38.35)

1.911

0.056

凝血酶时间*

16.8 (16.1, 18)

17.5 (16.9, 18.03)

2.605

0.009

谷丙转氨酶(ALT)

13 (9.18.5)

12 (8.75, 18.25)

0.13

0.999

谷草转氨酶(AST)

17 (13.5, 19.5)

17 (15, 20.25)

1.414

0.157

总胆红素*

6.2 (4.75, 8)

8.65 (5.98, 11.53)

3.234

0.001

白蛋白*

41.71 ± 4.18

44.06 ± 3.11

−3.22

0.002

球蛋白

29.2 (26.85, 33.2)

30.15 (27.4, 31.9)

0.218

0.828

肌酐(Cr)

59 (51.5, 66.5)

60 (52.75, 68)

0.426

0.67

肾小球滤过率

104.33 (94.51, 108.32)

105.47 (94.72, 110.10)

0.422

0.673

TSH

1.63 (1.10, 2.62)

1.44 (1.05, 2.02)

0.91

0.363

注:MLR:外周血单核细胞与淋巴细胞比值;PLR:外周血血小板与淋巴细胞比值;TSH:促甲状腺激素(thyroid stimulating hormone);*P < 0.05。

4. 讨论

子宫腺肌病是一种雌激素依赖性炎症性疾病,好发于育龄期妇女,发病率达7%~23%。与多种症状相关,包括痛经、月经量过多和不孕[2]。研究表明子宫腺肌病患者可能存在高凝状态,这可能和子宫腺肌病患者炎症、组织因子表达增加、经期出血过多有关[7]-[12]

然而,既往的研究均停留在分子生物学水平[7]。本研究从临床常用生化检验中探讨子宫腺肌病患者的生化特征。结果显示腺肌组患者炎症检验指标及凝血相关检验指标与对照组存在差异,具有统计学意义。腺肌组患者较对照组单核细胞、血小板、MLR、PLR水平表达增高,而血红蛋白、总胆红素、白蛋白、凝血酶时间水平表达下降。

研究表明外周血中单核细胞与淋巴细胞比值(MLR)和血小板与淋巴细胞比值(PLR)与全身炎症状态和免疫功能相关。炎症反应引起单核细胞[13] [14]向炎症部位的迁移和激活,吸引中性粒细胞和淋巴细胞。导致血液中单核细胞数量相对增加,而淋巴细胞则因被招募至炎症部位而数量减少,最终导致MLR升高。而血小板在炎症中被激活,与多种细菌及免疫细胞相互作用,形成血小板–白细胞复合物等,导致PLR升高。PLR与MLR易于检测且结果稳定,作为新的炎症指标被广泛应用于手术创伤、宫颈癌、急性胰腺炎、脓毒血症等相关性研究[15] [16]。本研究通过分析临床子宫腺肌病患者检验资料发现,子宫腺肌病患者相较对照组体内单核细胞、血小板、MLR、PLR表达增加,提示子宫腺肌病患者可能存在慢性炎症的状态。

胆红素具有强抗氧化、抑制炎症反应、保护细胞的作用。其通过减少炎症介质TNF-α、IL-1β和IL-6的产生,阻止炎症细胞的浸润和积聚而发挥抗炎症作用[17] [18]。众多研究表明,血清胆红素与慢性炎症相关疾病严重程度呈负相关。如:较高的血清胆红素水平与冠状动脉粥样硬化中纤维斑块的增加和斑块负担的减少呈正相关,同时与冠状动脉粥样硬化和钙化斑块的严重程度呈负相关。此外,较低的血清胆红素水平被认为是糖尿病及其相关炎症性疾病的独立预测因素,而在感染性心内膜炎患者中,较高的胆红素水平则可能与术后长期死亡率增加相关[19]-[22]。本研究中腺肌病患者体内胆红素相较其他良性妇科疾病患者升高,进一步支持子宫腺肌病呈现慢性炎症状态。

白蛋白是血浆中的主要蛋白质,负责维持血浆的渗透压。当人体处于贫血状态时,身体可能会优先分配白蛋白到其他重要器官,导致血清中白蛋白水平降低[23] [24]。血红蛋白是反映体内失血情况的指标之一,本研究显示,子宫腺肌病患者血清白蛋白水平、血红蛋白水平均较对照组低,呈现低营养状态,这可能与子宫腺肌病患者月经量增多有关。

凝血酶时间则是评估凝血功能的常用指标,凝血酶时间水平降低提示体内抗凝物质水平下降,凝血功能异常[25]。在本研究中,子宫腺肌病患者凝血酶时间较对照组降低,提示子宫腺肌病患者长期月经过多、经期延长导致了凝血功能异常,可能存在高凝状态。

由于本研究纳入实验的样本量较小,证据水平有限,在后续研究中需扩大样本量进行大规模、多中心临床试验来进一步验证该结论。以期对子宫腺肌病的临床诊断、预防、治疗提供依据。

5. 小结

综上所述,子宫腺肌病患者单核细胞、血小板、MLR、PLR水平表达增高,而血红蛋白、总胆红素、白蛋白、凝血酶时间水平表达下降。呈现出一定的炎症反应状态、低营养状态、高凝状态。

基金项目

广东省中医院李维贤学术经验传承工作室项目(编号:E43719)。

利益冲突

本文所有作者均声明不存在利益冲突。

NOTES

*第一作者。

#通讯作者。

参考文献

[1] Chapron, C., Vannuccini, S., Santulli, P., Abrão, M.S., Carmona, F., Fraser, I.S., et al. (2020) Diagnosing Adenomyosis: An Integrated Clinical and Imaging Approach. Human Reproduction Update, 26, 392-411.
https://doi.org/10.1093/humupd/dmz049
[2] Zhai, J., Vannuccini, S., Petraglia, F. and Giudice, L.C. (2020) Adenomyosis: Mechanisms and Pathogenesis. Seminars in Reproductive Medicine, 38, 129-143.
https://doi.org/10.1055/s-0040-1716687
[3] Upson, K. and Missmer, S.A. (2020) Epidemiology of Adenomyosis. Seminars in Reproductive Medicine, 38, 89-107.
https://doi.org/10.1055/s-0040-1718920
[4] Bulun, S.E., Yildiz, S., Adli, M. and Wei, J. (2021) Adenomyosis Pathogenesis: Insights from Next-Generation Sequencing. Human Reproduction Update, 27, 1086-1097.
https://doi.org/10.1093/humupd/dmab017
[5] Bourdon, M., Santulli, P., Jeljeli, M., Vannuccini, S., Marcellin, L., Doridot, L., et al. (2020) Immunological Changes Associated with Adenomyosis: A Systematic Review. Human Reproduction Update, 27, 108-129.
https://doi.org/10.1093/humupd/dmaa038
[6] Yu, O., Schulze-Rath, R., Grafton, J., Hansen, K., Scholes, D. and Reed, S.D. (2020) Adenomyosis Incidence, Prevalence and Treatment: United States Population-Based Study 2006-2015. American Journal of Obstetrics and Gynecology, 223, 94.e1-94.e10.
https://doi.org/10.1016/j.ajog.2020.01.016
[7] 徐凡, 郭方圆, 何燕, 等. 子宫腺肌病患者外周血血细胞及凝血功能的临床分析[J]. 昆明医科大学学报, 2021, 42(11): 128-133.
[8] Lin, Q., Li, T., Ding, S., Yu, Q. and Zhang, X. (2022) Anemia-Associated Platelets and Plasma Prothrombin Time Increase in Patients with Adenomyosis. Journal of Clinical Medicine, 11, Article No. 4382.
https://doi.org/10.3390/jcm11154382
[9] Coskun, B., Ince, O., Erkilinc, S., Elmas, B., Saridogan, E., Coskun, B., et al. (2020) The Feasibility of the Platelet Count and Mean Platelet Volume as Markers of Endometriosis and Adenomyosis: A Case Control Study. Journal of Gynecology Obstetrics and Human Reproduction, 49, Article ID: 101626.
https://doi.org/10.1016/j.jogoh.2019.101626
[10] Muraoka, A., Suzuki, M., Hamaguchi, T., Watanabe, S., Iijima, K., Murofushi, Y., et al. (2023) Fusobacterium Infection Facilitates the Development of Endometriosis through the Phenotypic Transition of Endometrial Fibroblasts. Science Translational Medicine, 15, eadd1531.
https://doi.org/10.1126/scitranslmed.add1531
[11] Cernogoraz, A., Schiraldi, L., Bonazza, D. and Ricci, G. (2018) Menstruation-Related Disseminated Intravascular Coagulation in an Adenomyosis Patient: Case Report and Review of the Literature. Gynecological Endocrinology, 35, 32-35.
https://doi.org/10.1080/09513590.2018.1488956
[12] Yang, F., Wang, Q., Ma, R., Deng, F. and Liu, J. (2024) Ca125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis. Journal of Multidisciplinary Healthcare, 17, 251-261.
https://doi.org/10.2147/jmdh.s435365
[13] Tudurachi, B., Anghel, L., Tudurachi, A., Sascău, R.A. and Stătescu, C. (2023) Assessment of Inflammatory Hematological Ratios (NLR, PLR, MLR, LMR and Monocyte/HDL-Cholesterol Ratio) in Acute Myocardial Infarction and Particularities in Young Patients. International Journal of Molecular Sciences, 24, Article No. 14378.
https://doi.org/10.3390/ijms241814378
[14] Russell, C.D., Parajuli, A., Gale, H.J., Bulteel, N.S., Schuetz, P., de Jager, C.P.C., et al. (2019) The Utility of Peripheral Blood Leucocyte Ratios as Biomarkers in Infectious Diseases: A Systematic Review and Meta-Analysis. Journal of Infection, 78, 339-348.
https://doi.org/10.1016/j.jinf.2019.02.006
[15] Ke, J., Qiu, F., Fan, W. and Wei, S. (2023) Associations of Complete Blood Cell Count-Derived Inflammatory Biomarkers with Asthma and Mortality in Adults: A Population-Based Study. Frontiers in Immunology, 14, Article ID: 1205687.
https://doi.org/10.3389/fimmu.2023.1205687
[16] Liu, K., Tang, S., Liu, C., Ma, J., Cao, X., Yang, X., et al. (2024) Systemic Immune-Inflammatory Biomarkers (SII, NLR, PLR and LMR) Linked to Non-Alcoholic Fatty Liver Disease Risk. Frontiers in Immunology, 15, Article ID: 1337241.
https://doi.org/10.3389/fimmu.2024.1337241
[17] Maruhashi, T., Kihara, Y. and Higashi, Y. (2019) Bilirubin and Endothelial Function. Journal of Atherosclerosis and Thrombosis, 26, 688-696.
https://doi.org/10.5551/jat.rv17035
[18] Zhao, X., Duan, B., Wu, J., Huang, L., Dai, S., Ding, J., et al. (2024) Bilirubin Ameliorates Osteoarthritis via Activating Nrf2/Ho‐1 Pathway and Suppressing NF‐κB Signalling. Journal of Cellular and Molecular Medicine, 28, e18173.
https://doi.org/10.1111/jcmm.18173
[19] Jain, V., Ghosh, R.K., Bandyopadhyay, D., Kondapaneni, M., Mondal, S., Hajra, A., et al. (2021) Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence. Current Problems in Cardiology, 46, Article ID: 100431.
https://doi.org/10.1016/j.cpcardiol.2019.06.003
[20] Vítek, L. and Tiribelli, C. (2021) Bilirubin: The Yellow Hormone? Journal of Hepatology, 75, 1485-1490.
https://doi.org/10.1016/j.jhep.2021.06.010
[21] Li, Y.-Y., Wang, H. and Zhang, Y.-Y. (2023) Serum Creatinine to Bilirubin Ratio Associated with Essential Hypertension. European Review for Medical and Pharmacological Sciences, 27, 580-591.
[22] Novák, P., Jackson, A.O., Zhao, G. and Yin, K. (2020) Bilirubin in Metabolic Syndrome and Associated Inflammatory Diseases: New Perspectives. Life Sciences, 257, Article ID: 118032.
https://doi.org/10.1016/j.lfs.2020.118032
[23] Zhang, H.Y., Wang, A.Q., Zhu, S., et al. (2022) Changes of Coagulation Function in Patients with Adenomyosis. Chinese Journal of Obstetrics and Gynecology, 57, 179-189.
[24] Manolis, A.A., Manolis, T.A., Melita, H., Mikhailidis, D.P. and Manolis, A.S. (2022) Low Serum Albumin: A Neglected Predictor in Patients with Cardiovascular Disease. European Journal of Internal Medicine, 102, 24-39.
https://doi.org/10.1016/j.ejim.2022.05.004
[25] Dorgalaleh, A., Favaloro, E.J., Bahraini, M. and Rad, F. (2020) Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). International Journal of Laboratory Hematology, 43, 21-28.
https://doi.org/10.1111/ijlh.13349